Ropivacaine Transdermal - tesa Labtec
Alternative Names: Ropivacaine Transdermal patch - tesa LabtecLatest Information Update: 31 Dec 2021
Price :
$50 *
At a glance
- Originator tesa Labtec
- Class Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Pain in Germany (Transdermal, Patch)
- 09 May 2017 Ropivacaine Transdermal is available for licensing as of 09 May 2017. www.tesa-labtec.com
- 09 May 2017 Preclinical trials in Pain in Germany (Transdermal)